Article Text

Download PDFPDF
1139 Prognostic implications of hematological indices in cervical cancer patients treated with concurrent chemo-radiotherapy
  1. Monal Garg,
  2. Priya Bhati,
  3. Ajay Sasidharan,
  4. K Sruthi,
  5. Debnarayan Dutta,
  6. K Pavithran and
  7. Gautham Balaji
  1. Amrita Institute of Medical Sciences, Kochi, India


Introduction/Background This study aims to determine the association of hematological indices like Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Albumin Globulin Ratio (AGR) with Overall Survival (OS) in cervical cancer patients treated with Concurrent Chemo-Radiotherapy (CCRT).

Methodology This study was conducted retrospectively between January 2016 till December 2019 in Amrita Institute of Medical Sciences. Patients with any stage who received definitive radiotherapy and/or chemotherapy and followed up-to at least 2 years post treatment were included. Receiver Operating Characteristic curves were used to determine the cut-off values for hematological indices. Kaplan-Meier analysis was done to calculate Overall Survival (OS), Progression-Free survival (PFS) and Recurrence-Free Survival (RFS).

Results A total of 123 patients were included. Mean age was 68 years. Majority of the patients presented with stage IIB (n=48, 39%). Squamous cell histology was seen in 94 patients (76.4%). Ninety-nine patients (81.4%) were treated with CCRT and 24 patients (19.6%) with only RT. Seven patients (5.6%) had disease progression and 17 patients (13.8%) experienced recurrences. With a median follow-up of 56 months, 5-year OS was 67.3 months, PFS was 84.8 months and RFS was 77.8 months. AGR (p = 0.001), NLR (p = 0.0001) and PLR (p = 0.001) were found significantly associated with OS, NLR (p= 0.002) and AGR (p = 0.001) significantly affected RFS while only PLR (p = 0.02) significantly affected PFS on univariate analysis. NLR significantly impacted OS (p = 0.003) and RFS (p = 0.03) on multi-variate analysis.

Conclusion This study reflects that NLR has a profound effect on the prognosis of cervical cancer patients treated with CCRT. Thus, pre-treatment hematological indices may be used as predictive markers for determining clinical outcomes in cervical cancer patients planned for upfront CCRT.

Disclosures None.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.